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Abstract 
Background: MON89788 was the first genetically engineered soybean worldwide to express a Bt toxin. Under the 
brand name Intacta, Monsanto subsequently engineered a stacked trait soybean using MON89788 and MON87701—
this stacked soybean expresses an insecticidal toxin and is, in addition, tolerant to glyphosate. After undergoing risk 
assessment by the European Food Safety Authority (EFSA), the stacked event was authorised for import into the EU in 
June 2012, including for use in food and feed. This review discusses the health risks associated with Bt toxins present 
in these genetically engineered plants and the residues left from spraying with the complementary herbicide.
Results: We have compared the opinion published by EFSA [1] with findings from other publications in the scientific 
literature. It is evident that there are several issues that EFSA did not consider in detail and which will need further 
assessment: (1) There are potential combinatorial effects between plant components and other impact factors that 
might enhance toxicity. (2) It is known that Bt toxins have immunogenic properties; since soybeans naturally contain 
many allergens, these immunogenic properties raise specific questions. (3) Fully evaluated and reliable protocols for 
measuring the Bt concentration in the plants are needed, in addition to a comprehensive set of data on gene expres‑
sion under varying environmental conditions. (4) Specific attention should be paid to the herbicide residues and their 
interaction with Bt toxins.
Conclusions: The case of the Intacta soybeans highlights several regulatory problems with Bt soybean plants in the 
EU. Moreover, many of the issues raised also concern other genetically engineered plants that express insecticidal 
proteins, or are engineered to be resistant to herbicides, or have those two types of traits combined in stacked events. 
It remains a matter of debate whether the standards currently applied by the risk assessor, EFSA, and the risk manager, 
the EU Commission, meet the standards for risk analysis defined in EU regulations such as 1829/2003 and Directive 
2001/18. While this publication cannot provide a final conclusion, it allows the development of some robust hypoth‑
eses that should be investigated further before such plants can be considered to be safe for health and the environ‑
ment. In general, the concept of comparative risk assessment needs some major revision. Priority should be given to 
developing more targeted approaches. As shown in the case of Intacta, these approaches should include: (i) sys‑
tematic investigation of interactions between the plant genome and environmental stressors as well as their impact 
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Background
After undergoing risk assessment by EFSA, the genetically 
engineered stacked soybean MON87701 × MON89788, 
produced by Monsanto and sold under the brand name 
Intacta, was authorised for import and use in food and 
feed in the EU [1]. The soybeans combine the expres-
sion of an insecticidal Bt toxin, Cry1Ac, present in the 
parental event MON87701, with herbicide resistance to 
glyphosate from parental event MON89788. While Bt 
toxins are expressed in several genetically engineered 
maize and cotton plant events, MON87701 and its stack 
MON87701 × MON89788 are the first Bt soybean varie-
ties cultivated in countries, such as Brazil and Argentina, 
to be given authorisation for import into the EU. This 
review discusses some specific health risks posed by the 
genetically engineered soybeans and the risk assessment 
undertaken by the European Food Safety Authority based 
on the data from the company Monsanto, which carried 
out field trials in the US and Argentina [1].
Monsanto, however, did not investigate any combina-
torial health effects emerging from the stacked trait. The 
data provided by the applicant concern acute toxicity 
testing with a high dosage of the isolated Bt toxin in mice 
[2]. In addition, they provided two 90-day studies with 
meal derived from MON87701; the data from these stud-
ies showed a range of uncertainties, such as significant 
changes in body weight [2]. Monsanto also provided data 
on allergenicity [1, 2]. Some of the findings are discussed 
in the relevant passages below.
We elaborate on potential health impacts due to toxic, 
immunogenic or combinatorial effects involving the Bt 
toxins, and on the residues from spraying with the com-
plementary herbicide. As yet, there has not been a fully 
comprehensive review of possible health impacts due to 
Bt toxins expressed in genetically engineered plants in 
interaction with constituents from soybeans that, in addi-
tion, are resistant (used herein as a synonym for ‘toler-
ant’) to glyphosate or other herbicides.
Assessment of the toxicity of Bt toxins
When reviewing existing data, it has to be taken into 
account that most of the data on the toxicity of Bt toxins 
are generated by using organisms primarily relevant for 
environmental risk assessment. But several conclusions 
derived from these data are also relevant for the health 
risk assessment of food and feed derived from Bt crops, 
especially if other specific data are not available or not 
sufficient. At the same time, the data provided by the 
applicant do not appear sufficient to draw final conclu-
sions: For example, an acute toxicity study with a high 
dosage of the isolated Bt toxin in mice [2]. This study 
does not allow conclusions to be drawn on the toxicity 
of exposure to the Bt toxin at lower dosages over longer 
periods of time. Furthermore, combinatorial effects that 
can emerge from the stacked event were completely left 
out of risk assessment.
Bt toxins are produced by soil bacteria Bacillus thur-
ingiensis [3]. In their native form, a subgroup of Bt tox-
ins, classified as Cry toxins, are mostly regarded as safe 
for human health and the environment because of their 
mode of action, that requires a basic pH and some spe-
cific receptors and enzymes [4]. The combination of these 
preconditions are known to occur in the gut of insects, 
but are absent in other animals such as vertebrates. In 
genetically engineered soybean MON87701, a specific Bt 
toxin is expressed, classified as Cry1Ac.
In contrast to native Bt toxins, there are several rea-
sons to assess in more detail the potential toxicity of Bt 
toxins expressed in genetically engineered plants: It is 
known that there are several differences in the structure 
of the Cry toxin expressed in the genetically engineered 
plants and those used in traditional mixtures [5, 6]. Tra-
ditionally, the Bt protoxin has been used for spraying as 
protoxin and in crystallised (inactivated) form. However, 
the Cry toxins expressed in the genetically engineered 
plants are already solubilised and activated. It is known 
that changes in the structure of the protein can have con-
siderable influence on the toxicity of the Bt proteins [7]. 
Therefore, the risk assessment taken from traditional Bt 
toxins used in biological pest control can only be applied 
to a limited extent to the Bt toxins expressed in plants.
Further, the Cry toxins are expressed by the plants 
throughout the whole period of vegetation, while the 
traditional sprays are used in a time-limited and tar-
geted manner, if necessary. The sprayed proteins can be 
expected to mostly degrade, while Bt toxins expressed in 
plants will be present in the harvest and—depending on 
further processing—will also be present in feed and food.
on gene expression and plant composition; (ii) detailed investigations of the toxicity of Bt toxins; (iii) assessment of 
combinatorial effects taking into account long‑term effects and the residues from spraying with complementary her‑
bicides; (iv) investigation into the impact on the immune and hormonal systems and (v) investigation of the impact 
on the intestinal microbiome after consumption. Further and in general, stacked events displaying a high degree of 
complexity due to possible interactions should not undergo a lower level of risk assessment than the parental plants.
Keywords: Genetically engineered plants, Bt toxins, Herbicide residues, Health effects, Risk assessment
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The mode of action of Cry toxins is not fully under-
stood. To some extent it is even a matter of controversial 
scientific debate [8, 9]. Several authors [10–14] reach dif-
ferent conclusions with regard to the mode of action in 
target organisms.
The mode of action is highly relevant for the risk 
assessment of Bt crops, since it is the scientific basis for 
assuming selectivity: The risk assessment of Bt toxins is 
mostly based on the concept that specific receptors are 
needed to bind and activate the toxin in the gut. How-
ever, there are several publications calling into question 
the role of some of the receptors [8, 10, 15]. Kitami et al. 
[16] show that Bt toxins can bind not only to specific 
receptors, but to various proteins that do not have many 
similarities with each other. Gómez et al. [7] summarise 
that oligomerisation in most cases depends on specific 
receptors, but at least toxicity in some mutant Bt proteins 
does not require these. Taken together, the role of some 
of the receptors in delivering the toxicity in target organ-
isms seems to be well established. However, there is also 
evidence that Bt proteins can exert toxicity by different 
modes of action, which are not as yet fully understood 
[7]. There are also uncertainties around the precise role 
of multiple putative receptors identified for individual 
toxins [9].
It is known that in vivo selectivity can differ consider-
ably from the expected selectivity stemming from the 
classification of Cry proteins, which is based on their 
structure [17]. Some of the gaps in the current under-
standing of the mode of action of Bt toxins and their 
importance for general risk assessment in non-target 
organisms were pointed out by Lövei et  al. [18]: “Even 
well-studied Cry toxins have an incompletely deter-
mined range of toxicity. Although it is clear that Cry1Ab 
and Cry1Ac are toxic mainly to Lepidopteran species, 
it is not yet possible to infer toxin specificity from toxin 
structure, and thus toxin specificity of a Cry toxin is a sci-
entific hypothesis, not a scientific fact. Moreover, trunca-
tion and mutagenesis of synthetic toxins might alter their 
range of toxicity compared with the native toxins”. Some 
of these uncertainties are summarised by Hilbeck and 
Otto [19], who come to the conclusion that “there is pres-
ently no way of predicting which species may or may not 
be affected based on the current state of understanding 
of the proposed modes of action of Cry toxins”.
These findings are very relevant for the health risk 
assessment of Bt crops, such as Intacta soybeans. Cer-
tainly, the absence of specific receptors in mammalian 
species is not sufficient to conclude that Bt proteins are 
not toxic for them. Potential effects might be subtle and 
show up only after chronic exposure. Besides the acute 
toxicity study already mentioned, Monsanto provided 
two subchronic 90-day studies with meal derived from 
MON87701 [2]. The data from these studies showed a 
range of uncertainties such as significant changes in body 
weight [2]. EFSA did not, however, request further feed-
ing studies over a longer period of time.
Further, no feeding studies with the stacked event were 
requested [1], and thus potential combinatorial effects 
remain untested. This means that substantial gaps remain 
in the risk assessment of the Intacta soybeans: Not only 
is the mode of action of the Cry proteins not fully under-
stood, there are also open questions regarding combina-
torial or cumulative effects. There are several publications 
pointing out that Bt proteins are highly likely to show 
synergies and interactions with other stressors and plant 
enzymes (for overview see [20]). For example, it is known 
that co-stressors, such as cadmium and nematodes, can 
cause toxicity of Cry toxins in slugs [21, 22], which can 
be taken as a relevant model organism. These experi-
ments are of general relevance for risk assessment since 
they show that even organisms that are not known to be 
susceptible to Cry proteins can be impacted if exposed 
to other stress factors. It can be hypothesised from these 
experiments, that co-stressors can render toxicity of Bt 
toxins independently of the presence of specific known 
receptors. Thus, selectivity of Bt toxins as expected from 
experiments with organisms exposed to the Bt toxins 
alone might not be observed in combination with other 
stressors.
Multiple challenges or stressors continuously affecting 
organisms can be regarded as the normal real-life situ-
ation in the field as well as in regard to consumption of 
food and feed. Additive or synergistic effects of Bt toxins 
in combination with other stressors are also relevant for 
the health risk assessment of Intacta soybeans. Although 
empirical data on mammals are mostly lacking, the data 
that are available can be used to derive robust hypothe-
ses for further investigation of health risks: Combinato-
rial effects are known to enhance the toxicity of Bt toxins 
in invertebrates and have been observed in experiments 
with pyrethroids [23], azadirachtin, [24], avidin [25], 
bacteria [14], nosema [26] and other Bt toxins [27, 28]. 
Since the stacked Intacta soybeans and food and feed 
derived thereof are likely to contain residues from spray-
ing with glyphosate formulations, the possible interaction 
between Bt toxins and co-stressors, such as pesticides, 
are relevant to the health risk assessment.
Other examples of synergies that are specifically rel-
evant for the health risk assessment of Intacta soybeans 
include the effect that protease inhibitors can have on 
the toxicity of Bt toxins: Such an inhibition could delay 
the digestion of proteins, including Cry toxins, and thus 
enhance toxicity by prolonged or increased exposure. An 
up to 20-fold increase of toxicity was found even in the 
presence of very low levels of protease inhibitors [29–31]. 
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Soybeans are known to show high levels of such inhibi-
tors e.g. the trypsin-inhibitor [32]. The degradation of 
these proteinase inhibitors in the soybeans will depend 
on the method of heat processing. There are several 
methods, such as micronisation, roasting, expanding, 
extrusion or hydrothermal processing, that all work with 
different temperatures and durations [33]. Germination 
is used, for example, to produce soymilk [34]. The meth-
ods used will depend on the product to be placed on the 
market [35] as well as on the variety used [32]. The deg-
radation of the inhibiting proteins will vary, but they will 
not be removed completely [32].
Several combinatorial mechanisms that can enhance 
the toxicity of Bt toxins have thus far been described; 
these are also relevant for the risk assessment of plants 
expressing these toxins. However, none of these mecha-
nisms were discussed by EFSA when assessing Intacta 
or its parental plants. Table 1 gives an overview of some 
of the relevant combinatorial effects of Bt toxins. While 
some combinatorial effects might only occur under some 
circumstances, protease inhibitors are abundant in soy-
beans, and therefore need to be taken into account in the 
risk assessment of Bt soybeans. Furthermore, residues 
from spraying with herbicide formulas based on glypho-
sate are particularly relevant as additional stressors, since 
these residues can be expected to be present in most soy-
beans harvested from Intacta.
As yet, most of the findings on combinatorial effects 
stem from organisms that are relevant for environ-
mental risk assessment, but these are also relevant for 
health risks. In addition, there are findings in mamma-
lian species showing that Bt toxicity is a relevant topic 
for detailed health risk assessment: Some Cry toxins are 
known to bind to epithelial cells in the intestines of mice 
[36, 37]. As far as potential effects on health are con-
cerned, several authors [38–43] show that Cry proteins 
could potentially have an impact on the health of mam-
mals. Also de Souza Freire et al. [44] confirm haematox-
icity of several Cry toxins. Some of these effects seem to 
occur where there are high concentrations and tend to 
become stronger after several days. Such observations 
highlight the need to study the effects after long-term 
exposure to lower dosages and/or in combination with 
relevant herbicides as described above.
Assessement of immune system responses
Effects of Bt toxins on the immune system have been 
identified in different species and via different routes, 
including whole food dietary administration. The obser-
vations include studies on mice [45, 46], and pigs [47, 48]. 
Immune system responses have also been shown for fish 
[49, 50]. Based on data that were provided to the Indian 
authorities by Monsanto, Gallagher [51] also assumed 
immunotoxic reactions in rats: Rats fed with Bt auber-
gine-producing Cry1Ac protein were significantly less 
healthy than controls as demonstrated by an increased 
white blood cell count, eosinophils in particular, and 
enlarged spleens. Further hepatotoxic effects included 
elevated bilirubin and acetylcholinesterase.
Rubio-Infante and Moreno-Fierros [52] summa-
rised some findings regarding the Cry1Ac toxin and its 
effect on the immune system. They classify Cry1Ac as a 
potent mucosal and systemic immunogen and adjuvant 
[36, 53]. They mention the high immunogenicity of the 
Cry1Ac protoxin demonstrated by its capacity to induce 
significant specific antibody responses in serum and 
mucosal-secretions recovered from the small and large 
intestine, bronchoalveolar and vaginal lavages of mice 
after immunisation by every tested route, such as intra-
peritoneal, intragastric, intranasal, rectal [36, 54] and 
vaginal [55]. In summary, the adjuvant effects of Cry1Ac 
protoxin were evaluated regarding the specific antibody 
responses attained at both mucosal and systemic lev-
els to co-administered antigens of different nature. In a 
further publication [56], it is shown in more detail how 
Cry1Ac induces macrophage activation. Rubio-Infante 
and Moreno-Fierros [52] conclude further risk research 
is necessary: “(…) the immunogenicity of these proteins 
and their possible risks in humans after short- and long-
term exposure must be determined. Evaluation of the 
risks of Cry proteins in other systems such as the respira-
tory and nervous systems is also needed. The toxicity def-
inition must include the adverse effects caused by these 
toxins not only in the short term; therefore, subchronic 
Table 1 Overview of some combinatorial effects of Bt toxins known to enhance toxicity
Description of combinatorial effects known to enhance  
toxicity of Bt toxins
Some references
Availability of specific co‑factors Broderick et al. [12]
Parallel or successive exposure to biotic and/or abiotic stressors Kramarz et al. [21], Kramarz et al. [22], Khalique and Ahmed [23], Singh 
et al. [24], Zhu et al. [25], Mason et al. [14], Reardon et al. [26]
Delaying degradation of Bt toxins by plant enzymes (protease inhibitors) Zhang et al. [29], Zhu et al. [30], Pardo Lopez et al. [31]
Other Bt toxins Sharma et al. [27], Tabashnik et al. [28]
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and chronic studies in humans should be performed, and 
the immunotoxicological features of these toxins should 
be determined”.
The relevance of these questions for the risk assessment 
of food and feed is evident: Immune system responses 
can have various impacts on health, especially under per-
manent or long-term exposure. For example, the Univer-
sity of Manchester [57] identified several diseases, such 
as Coeliac disease, food protein-induced enterocolitis 
and food protein-induced enteropathies, that can be 
associated with non-IgE-mediated immune adverse reac-
tions to foods.
In particular, Cry1Ac which is expressed in Intacta soy-
beans is known to also act as an adjuvant that can boost 
immune reactions to antigens [52]; thus the Bt toxin can 
for example enhance the reaction of the immune system 
to allergens being present in the diet. This is particularly 
relevant in the case of Bt soybeans, since soybeans (i.e. 
some of their proteins) belong to the group of food plants 
categorised as known human allergens [58, 59].
As far as the MON87701 modified soybean is con-
cerned, the only empirical investigation on immune sys-
tem responses to this soybean provided by the applicant 
was carried out with 13 samples from sera from patients 
with known allergic reaction to soybeans [60, 61]. In the 
case of MON89788, it was restricted to 16 such samples 
[62, 63]. For MON87701, the outcome was unclear, there 
were some differences when comparing the samples with 
the controls, which were difficult to interpret. Although 
submitted as regulatory documents, none of the studies 
met the Good Laboratory Practice (GLP) quality stand-
ards [60–62]. In addition, Rice et  al. [63] did not make 
any statement on GLP. No empirical testing was per-
formed with the stacked event.
The investigations were carried out with a very low 
number of samples. It is surprising therefore that EFSA 
accepted these studies: As the minutes of a meeting of 
the working group (WG) “Self Task on Allergenicity” 
from 24 September 2007 show, experts from EFSA had 
serious doubts about the reliability of investigations with 
sera from patients with known allergic reaction to soy-
beans as performed in this case. According to the min-
utes [64], “More sera from patients are needed but they 
also need to be well-characterised. Statistical calculations 
have been done showing that 60–70 well-characterised 
sera are needed based on variability. Since this might not 
be feasible, the WG has to consider the reliability of stud-
ies with a lower number of sera”.
Further EFSA guidance [65] requires specific investiga-
tions to exclude risks for children and elderly people if 
risks concerning the immune system have to be assessed: 
“The specific risk of potential allergenicity of GM prod-
ucts in infants as well as individuals with impaired 
digestive functions (e.g. elderly people, or individuals on 
antacid medications) should be considered, taking into 
account the different digestive physiology and sensitivity 
towards allergens in this subpopulation”. However, these 
specific risks for infants and other relevant groups were 
left aside during EFSA risk assessment for Intacta and its 
parental plants [1, 2].
Besides the test with sera from patients, potential 
allergenicity in parental plants was assessed by applying 
a pepsin digestion assay. As a result, the Cry protein is 
thought to degrade rapidly in the gastrointestinal tract 
and the risk of triggering immune system responses was 
regarded as being low. However, Chowdhury et  al. [66] 
and Walsh et al. [47] have found Cry1Ab proteins in the 
lower part of the gastrointestinal tract of pigs fed with 
a diet containing Bt maize. This directly challenges the 
above-mentioned view of rapid degradation of Cry1A 
proteins in the stomach. It appears that the Cry1A pro-
teins can show a much higher stability in monogas-
tric species than predicted by current in  vitro digestion 
experiments. Further, and more specifically in regard 
to Intacta soybeans, it has to be taken into account that 
the Cry protein expressed in the soybeans might be 
much more resistant to degradation than that expressed 
in maize, due to the occurrence of a higher level of pro-
teinase inhibitors. Thus, Bt toxins are not likely to be 
degraded rapidly in the gut and can persist in larger 
amounts until digestion is complete and there is enough 
time for interaction between various food compounds. 
The need for further investigations was also confirmed 
by Guimaraes et al. [67], who showed that Cry1Ab pro-
teins were stable and conserved their immunoreactivity 
by using a physiologically more relevant digestion model. 
In addition, a study commissioned by EFSA [68] shows 
that the in vitro pepsin tests used to date are not likely to 
provide reliable results.
To summarise some of the findings, for the soybean 
Intacta and its parental plant MON87701, there are two 
factors that indicate a higher risk to the immune sys-
tem in comparison to other plants such as Bt maize and 
Bt cotton. These two factors should be used for further 
hypothesis-driven research. Firstly, soybeans produce 
protease inhibitors that can prolong exposure to Bt pro-
teins during digestion and therefore increase the likeli-
hood of immune system responses. Secondly, soybeans 
produce many plant allergens, and there is a specific 
risk that the Bt protein can enhance the immune system 
response to these compounds at the consumption stage.
In assessing these questions, it should also be taken 
into account that Bt toxins from other transgenic plants, 
such as stacked maize, can be mixed with the soybeans in 
the diet and thereby enhance immune system responses 
based on the mechanisms identified, even if the soybeans 
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do not express Bt toxins themselves. For example, geneti-
cally engineered plants, such as the genetically engi-
neered maize ‘Smartstax’ (MON89034 ×  1507 ×  MON
88017  ×  59122), express up to six Bt toxins, resulting 
in a much higher concentration of the potentially immu-
nogenic proteins. We are not aware of studies that have 
investigated the impact on the immune system of con-
suming food or feed derived from these plants alone or in 
combination with soybeans.
Assessing the Bt concentration
Interaction with environmental stressors and extreme 
weather conditions relevant in times of climate change, 
such as drought, can also impact the Bt concentration 
in the plants [69]. Huge variations in Bt concentration 
have, for instance, been found in genetically engineered 
cotton plants [70]. As known from other cases—such 
as MON810 (a genetically engineered maize express-
ing Cry1Ab Bt toxin), independent research [71] has 
shown that the data provided by industry do not show 
the true range of variation of Bt toxins in the plants. 
Trtikova et al. [72] show that the stress reactions of maize 
MON810 are not predictable. In the case of the geneti-
cally engineered soybeans MON87701 and the stacked 
event Intacta, there have been no independent and sys-
tematic investigations to determine the Bt concentration 
in varying environmental conditions. As a result, the true 
range of variation of Bt concentration in the plants is not 
fully known.
Furthermore, in comparison to the parental plants, the 
stacked soybean Intacta tends towards a higher concen-
tration of the newly expressed proteins in its tissues as 
well as a higher degree of standard deviation [73]. This 
indicates emerging genomic effects in the stacked soy-
beans or other interactions that cannot necessarily be 
predicted from the parental plants. The relevant data 
available in this regard (see Table  2) are derived from a 
small number of samples and from only one season.
In general, fully evaluated protocols able to deliver 
reproducible and comparable results are needed to 
determine the true range of variation of Bt concentra-
tion in the plants and the expression rate of the newly 
introduced proteins. It is known that slight differences 
in the method/protocol used in measuring using ELISA 
can lead to huge differences in the results [6]. However, 
no validated method has as yet been made available to 
independent laboratories for Cry1Ac expressed in the 
soybeans, with the result that major uncertainties remain 
about the exact concentration of Bt toxin expressed in 
the plants.
There is a further requirement for data relating to the 
effect processing has on the Bt proteins under a suf-
ficiently broad range of technical conditions. As far as 
the effects of processing on the derived products are 
concerned, the soybeans have only been subjected to 
one specific kind of heat processing, chosen by Mon-
santo without any clear justification [74]. As Bell et  al. 
[74] state: “The temperature (~190  °C) and duration 
(~15 min) used in this assessment were selected to rep-
resent a baking treatment that might be employed in the 
production of foods that contain soybean flour”.
As already mentioned, there are several methods, such 
as micronisation, roasting, expanding, extrusion, hydro-
thermal processing and germination, that all work with 
different temperatures and durations. Germination is a 
method used, for example, to produce soymilk [33]. The 
methods used will depend on the product to be placed on 
the market [34] as well as on the variety of soybean [35]. 
The degradation of the inhibiting proteins will vary, but 
they will not be removed completely [35]. Most of these 
standard methods work with temperatures much lower 
than 190 °C. In general, each processing company might 
also prefer to vary the standardised methods, since the 
goal of the processing is not only to degrade anti-nutri-
tional compounds, such as trypsin-inhibitors, but also to 
produce a food or feed product with high quality proteins 
and healthy compounds, such as isoflavones [34]. If the 
methods used particularly focus on the conservation of 
protein quality in the soybeans, this could result in the 
structure and function of the Bt toxin being preserved in 
food and feed.
In general, the method as described by Bell [74] can-
not be considered to be sufficient to assess the effect of 
processing on the concentration of Bt proteins in the 
plant. Very limited conclusions can be drawn on the fac-
tual exposure of consumers and animals if the soy is used 
in food and feed because there are no data on the effects 
from any other technical treatments used to process 
Table 2 Summary of Cry1Ac protein concentration in soy-
bean leaf tissues collected from MON87701 × MON89788 
in  comparison to  MON87701 grown in  Argentina dur-
ing 2007–2008 [73]
Number of samples per OSL: 14 for MON87701 and 15 for MON87701 × MON89034  
(see also list of abbreviations)
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soybeans. Since the authorisation is not limited to spe-
cific purposes, usage as soybean sprouts or soymilk may 
serve as examples where technical treatment is highly 
limited. Such products could reach the market without 
any further risk assessment.
To summarise, based on the current data, it is not pos-
sible to determine exposure to Bt toxins within the food 
and feed chain, although this would be directly relevant 
for the assessment of risks to the immune system as 
well as for other potential effects. The assumptions pre-
sented by the applicants concerning exposure of livestock 
and humans are not based on data derived from suffi-
ciently reliable methods. Further, the data presented do 
not show the true range of variations of Bt toxins in the 
plants grown under various environmental conditions.
It has to be stressed that these questions not only con-
cern genetically engineered soybeans that express Bt tox-
ins. And in assessing these questions, it should also be 
taken into account that Bt toxins from other transgenic 
plants, such as stacked maize, can be mixed with the soy-
beans in the diet and enhance immune system reactions 
based on the identified mechanisms.
Assessment of residues from spraying
Since Intacta soybeans not only produce an insecticidal 
toxin but are also tolerant to glyphosate, the question 
arises for the health risk assessment about specific resi-
dues from spraying and potential interactions with the Bt 
toxins.
In general, the risk assessment of genetically engineered 
herbicide-resistant plants currently performed by EFSA 
is divided into the assessment of the plant performed by 
the GMO-panel, and assessment of the pesticide per-
formed by the pesticide panel. However, this does not 
mean that if a pesticide is authorised for use in the EU, 
that no further investigation of the residues from spray-
ing with the complementary herbicide is needed. Due to 
the specific agricultural practices that go along with the 
cultivation of these herbicide-resistant plants, there are, 
for example, specific patterns of applications, exposure 
and occurrence of specific metabolites and an emergence 
of combinatorial effects that require special attention. 
For example, large-scale commercial cultivation of these 
plants results in a strong selective pressure on weeds to 
develop resistance to the herbicides [75]. This problem 
is also relevant for health risk assessment, since this has 
led to increasing amounts of glyphosate being sprayed 
[76] and subsequently more residues in the harvest [77]. 
Furthermore, herbicide-tolerant plants are engineered to 
survive the application of the complementary herbicide, 
while most other plants will die after a short time. Thus, 
for example, residues of glyphosate, its metabolites and 
additives to the formulated product might accumulate 
and interact in the plants, also changing the plant’s com-
position [78]. Finally, in stacked events, such as Intacta, 
a combination of specific plant constituents is present in 
the genetically engineered plants. The combination of the 
residues from spraying and of insecticidal proteins (as in 
the case of Intacta) leads to a unique pattern of combina-
torial exposure in the feed and food chain.
As a publication by Kleter et al. [79] shows, using herbi-
cides to spray genetically engineered herbicide-resistant 
plants does indeed lead to patterns of residues and expo-
sure that are not taken into account in regular pesticide 
registration: “1. GM herbicide-resistant crops can change 
the way that herbicides can be used on these crops, for 
example: (a) post-emergent over-the-top applications (i.e. 
on the crop itself ) instead of directed sprays, avoiding 
herbicide contact with the crop; or (b) pre-emergent and 
pre-harvest applications made to the conventional crop 
and not, or in different quantities, to the GM crop. 2. The 
residue profile of the applied pesticide may have been 
altered on the basis of the nature of the modification. 3. 
The overall pattern of pesticides applied to the particular 
crop may have been altered, leading to different exposure 
to pesticide residues overall”.
Thus, according to a reasoned legal opinion drawn up 
by Kraemer [80], from a regulatory point of view, resi-
dues from spraying with complementary herbicides have 
to be taken into account in the risk assessment of geneti-
cally engineered plants.
The EU pesticide regulation also requires specific 
risk assessment of imported plants if the usage of pesti-
cides is different in the exporting countries compared to 
countries in the EU: Recital 26 of Regulation 396/2005 
requires Maximum Residues Levels (MRLs) to be set for 
food and feed produced outside the Community if pro-
duced by different agricultural practices as regards the 
use of plant protection products. Article 14 of Regula-
tion 396/2005 requires that the presence of pesticide 
residues arising from sources other than current plant 
protection uses and their known cumulative and syn-
ergistic effects are determined. Further, Article 29 of 
Regulation 1107/2009 states that active substances and 
synergists have to be approved, and the maximum resi-
due levels for each specific agricultural product have to 
be determined.
Whatever the case may be, both the EU pesticide reg-
ulation and the GMO Regulation require a high level 
of protection for health and the environment. Thus, in 
regard to herbicide-resistant plants, the specific assess-
ment of residues from spraying with complementary 
herbicides must be considered to be a prerequisite for 
granting authorisation. In addition, additive or synergis-
tic effects need to be investigated if a plant contains or 
produces other compounds with potential toxicity.
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Consequently, authorisation for the import and usage 
in food and feed of genetically engineered plants cannot 
be granted if the plants contain residues from spraying 
with complementary herbicides that pose unacceptable 
risks, or are suspected of being harmful to the health of 
humans and/or animals.
A basic prerequisite for risk assessment in this context 
is the availability of valid and reliable data on residue 
loads from spraying with herbicides. This is especially 
relevant in the case of glyphosate: A study published in 
2015 by IARC [81] claimed that glyphosate is probably 
carcinogenic to humans. While carcinogenicity of the 
active ingredient remains a matter of debate [82], it is 
documented that additives and their mixtures used in the 
commercial formulations for spraying glyphosate show 
a much higher toxicity than the active ingredient alone 
[83].
The amount of residues depends on the specific agro-
nomic management used in the cultivation of the herbi-
cide-resistant plants. Data from publications show [77, 
78] a considerable amount of residues from spraying can 
be expected in genetically engineered soybeans that are 
resistant to glyphosate formulations. In general, the level 
of residues is likely to increase due to increasing prob-
lems with herbicide-resistant weeds [76]. However, there 
is a lack of reliable data covering the actual range of resi-
due load in the plants [79]. EFSA also stated in 2015 [84], 
that the safety of residues from spraying glyphosate for-
mulations could not be concluded on the data provided 
by the company. Thus, EFSA was unable to deliver a con-
clusive risk assessment on the actual risks of residues 
from spraying with glyphosate and the various glypho-
sate formulations used in the countries where such plants 
are cultivated. Therefore, the data regarding residues 
from spraying glyphosate on the genetically engineered 
soybeans do not meet the requirements of Regulation 
1107/2009 or Regulation 396/2005. However, neither the 
EU risk assessor nor the EU risk manager discussed this 
aspect.
In conclusion, the residues from spraying are inevitable 
constituents of the plant composition, leading to a spe-
cific pattern of exposure via food and feed that needs to 
be addressed during the authorisation process of geneti-
cally engineered herbicide-resistant plants.
Furthermore, in the context of the risk assessment 
of the stacked event Intacta, the residues from spray-
ing might interact with the Bt toxin and might act as 
a potent co-stressor. Thus, the combinatorial effects 
between the effects of glyphosate and the Bt toxins need 
to be assessed in more detail. For example, Kramarz 
et al. [21] show interaction with co-stressors can render 
toxicity of Bt proteins to organisms that are not suscepti-
ble to Bt toxins alone. In addition, Bøhn et al. [85] show 
that additive effects of several Cry toxins and Cry tox-
ins interact with Roundup/glyphosate when co-exposed. 
However, these aspects were not discussed during EU 
risk assessment.
In addition, there are some other issues related to 
residues from spraying with glyphosate that should 
be considered during the health risk assessment of 
Intacta soybeans. Two examples are mentioned here 
briefly:
There is a considerable amount of literature indicat-
ing that glyphosate formulations can act as so-called 
endocrine disruptors (see, for example, [86–89]). Since 
soybeans also produce a number of plant oestrogens 
with hormonal activity [90], there might be some syn-
ergistic or additive interaction with the residues from 
spraying with glyphosate formulations. However, 
potential impacts from the consumption of products 
derived from soybean MON89788 and Intacta on the 
hormonal system of mammals were not investigated.
A further example is the potential impact on the intes-
tinal microbiome. Such effects might be caused by the 
residues from spraying, since glyphosate was shown to 
have negative effects on the composition of the intestinal 
flora of cattle [91] and poultry [92]. In addition, Walsh 
et al. [93] also describe effects on the microbiota in pigs 
fed with Bt maize MON810. They consider these changes 
to be beneficial but point out that more investigations 
would be needed. No data on the potential impacts of 
Intacta soybeans on the intestinal microbiome have been 
published so far.
Conclusions
In regard to assessment of health risks, the case of Intacta 
highlights several regulatory problems with Bt soybean 
plants in the EU: (1) There are potential combinatorial 
effects between plant components and other impact fac-
tors that might enhance toxicity—this could also be rel-
evant for the assessment of herbicide residues in food 
and should, therefore, be investigated in more detail. (2) 
It is known that Bt toxins have immunogenic properties; 
since many allergens occur naturally in soybeans, these 
immunogenic properties raise specific questions regard-
ing health effects that so far have not been taken into 
account during risk assessment. (3) Fully evaluated and 
reliable protocols are needed to determine the Bt concen-
tration in the plants, in addition to a comprehensive set 
of data on gene expression under varying environmental 
conditions. Further, detailed data on the effects of pro-
cessing and intestinal degradation are needed to assess 
the exposure of the food chain to Bt toxins. Neither pro-
tocols nor detailed data were requested during the pro-
cess of authorisation for Intacta and its parental plants. 
(4) The permanent exposure to residues from spraying 
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with herbicides in combination with a mixture of Bt tox-
ins in the food chain requires specific approaches for risk 
assessment.
It remains a matter of discussion whether the stand-
ards currently applied by EFSA meet the requirements 
for risk assessment as defined in EU regulations such as 
1829/2003 and Directive 2001/18. In general, the con-
cept of comparative risk assessment needs some major 
revision. Priority should be given to more targeted 
approaches, such as the investigation of the plant reac-
tions to environmental stressors, risks to the immune 
and the hormonal system of mammalian species, com-
binatorial effects and long-term impact assessment of 
permanent consumption. Further, it does not make 
sense that stacked events showing a higher degree of 
complexity due to possible interactions should undergo 
a lower level of risk assessment than the parental 
plants.
In regard to the risk manager, the EU Commission, the 
current practice of authorisation does not appear to com-
ply with EU regulation requirements, such as 1829/2003 
and Directive 2001/18, that obligate a high level of pro-
tection for human health and the environment taking 
into account the precautionary principle as the underly-
ing paradigm.
Some of the issues, such as the assessment of toxic-
ity, immunogenic effects and the assessment of residues 
from complementary herbicides, are under the remit of 
the risk assessor, i.e. the European Food Safety Authority 
(EFSA). And some issues will require closer collaboration 
between the risk manager, i.e. the EU Commission and 
EFSA, including requesting industry to deliver protocols 
for measuring the Bt concentration in the plants and to 
close the gaps between pesticide regulation and GMO 
regulation.
Since further soybean varieties expressing Bt toxins 
are already in the pipeline of companies, such as Mon-
santo, these issues require urgent attention. Further, 
many of the issues raised also concern other genetically 
engineered plants that express insecticidal proteins or 
are engineered to be resistant to herbicides, or are being 
combined in stacked events.
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